LSV Asset Management Raises Stake in LivaNova PLC $LIVN

LSV Asset Management grew its holdings in shares of LivaNova PLC (NASDAQ:LIVN) by 25.4% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 674,610 shares of the company’s stock after acquiring an additional 136,600 shares during the quarter. LSV Asset Management owned 1.24% of LivaNova worth $35,336,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in LIVN. Invesco Ltd. grew its stake in LivaNova by 714.7% in the second quarter. Invesco Ltd. now owns 1,028,713 shares of the company’s stock worth $46,313,000 after purchasing an additional 902,447 shares during the period. Scopia Capital Management LP bought a new stake in shares of LivaNova during the 2nd quarter valued at $36,657,000. Artisan Partners Limited Partnership grew its position in shares of LivaNova by 112.9% in the 2nd quarter. Artisan Partners Limited Partnership now owns 1,247,609 shares of the company’s stock worth $56,167,000 after buying an additional 661,480 shares during the period. AQR Capital Management LLC increased its stake in shares of LivaNova by 30.5% in the 2nd quarter. AQR Capital Management LLC now owns 2,049,820 shares of the company’s stock worth $92,201,000 after acquiring an additional 478,525 shares in the last quarter. Finally, M&G PLC purchased a new position in LivaNova during the 2nd quarter valued at about $11,762,000. 97.64% of the stock is currently owned by institutional investors.

LivaNova Stock Performance

NASDAQ LIVN opened at $65.80 on Friday. The firm has a market capitalization of $3.59 billion, a P/E ratio of -16.45 and a beta of 0.97. The stock has a 50-day simple moving average of $63.62 and a two-hundred day simple moving average of $57.41. The company has a debt-to-equity ratio of 0.30, a quick ratio of 1.12 and a current ratio of 1.33. LivaNova PLC has a fifty-two week low of $32.48 and a fifty-two week high of $67.92.

Analyst Ratings Changes

Several research firms recently weighed in on LIVN. The Goldman Sachs Group restated a “neutral” rating and issued a $66.00 price target on shares of LivaNova in a research note on Friday, January 9th. Wall Street Zen raised LivaNova from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 20th. Mizuho raised their price target on LivaNova from $70.00 to $72.00 and gave the company an “outperform” rating in a report on Wednesday, December 17th. Stifel Nicolaus lifted their price target on LivaNova from $65.00 to $70.00 and gave the stock a “buy” rating in a research report on Wednesday, January 7th. Finally, KeyCorp started coverage on shares of LivaNova in a research report on Friday, December 19th. They set an “overweight” rating and a $81.00 price objective on the stock. Six investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $69.38.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.